AU2018288653A1 - Treatment of sexual dysfunction and improvement in sexual quality of life - Google Patents

Treatment of sexual dysfunction and improvement in sexual quality of life Download PDF

Info

Publication number
AU2018288653A1
AU2018288653A1 AU2018288653A AU2018288653A AU2018288653A1 AU 2018288653 A1 AU2018288653 A1 AU 2018288653A1 AU 2018288653 A AU2018288653 A AU 2018288653A AU 2018288653 A AU2018288653 A AU 2018288653A AU 2018288653 A1 AU2018288653 A1 AU 2018288653A1
Authority
AU
Australia
Prior art keywords
stem cells
mesenchymal stem
sexual
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018288653A
Other languages
English (en)
Inventor
Darcy L. DIFEDE
Joshua M. Hare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of AU2018288653A1 publication Critical patent/AU2018288653A1/en
Assigned to LONGEVERON LLC reassignment LONGEVERON LLC Request for Assignment Assignors: Difede, Darcy, LONGEVERON LLC
Assigned to LONGEVERON INC. reassignment LONGEVERON INC. Amend patent request/document other than specification (104) Assignors: LONGEVERON LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018288653A 2017-06-19 2018-06-15 Treatment of sexual dysfunction and improvement in sexual quality of life Abandoned AU2018288653A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762521765P 2017-06-19 2017-06-19
US62/521,765 2017-06-19
PCT/US2018/037725 WO2018236680A1 (en) 2017-06-19 2018-06-15 TREATMENT OF SEXUAL DYSFUNCTION AND IMPROVEMENT OF THE QUALITY OF SEXUAL LIFE

Publications (1)

Publication Number Publication Date
AU2018288653A1 true AU2018288653A1 (en) 2020-01-16

Family

ID=62952383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018288653A Abandoned AU2018288653A1 (en) 2017-06-19 2018-06-15 Treatment of sexual dysfunction and improvement in sexual quality of life

Country Status (12)

Country Link
US (1) US12496316B2 (enExample)
EP (1) EP3641793A1 (enExample)
JP (1) JP7343123B2 (enExample)
KR (1) KR20200017516A (enExample)
CN (1) CN111107858A (enExample)
AU (1) AU2018288653A1 (enExample)
CA (1) CA3067354A1 (enExample)
IL (1) IL271395A (enExample)
SG (1) SG11201912209UA (enExample)
TW (1) TW201919664A (enExample)
WO (1) WO2018236680A1 (enExample)
ZA (1) ZA201908451B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021340971A1 (en) 2020-09-08 2023-03-30 Longeveron, Inc. Treatment of Alzheimer's disease with allogeneic mesenchymal stem cells
EP4376950A1 (en) 2021-07-26 2024-06-05 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
CA3226181A1 (en) 2021-09-10 2023-03-16 Longeveron Inc. Treatment of aging frailty comprising administering bone marriw derived mesenchymal stem cells
KR102762783B1 (ko) * 2022-01-21 2025-02-05 고현서 심리 프로파일에 따른 행동 습관 제공 방법, 서버, 저장 매체 및 디바이스
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
WO2010021996A1 (en) * 2008-08-18 2010-02-25 Junta De Beneficiencia De Guayaquil Treatment of injuries to the central nervous system
EP2486930B1 (en) 2009-10-06 2016-03-23 National University Corporation Nagoya University Cell preparation containing adipose tissue derived mesenchymal stem cells for use in the treatment of a condition of no urge to urinate
WO2013173694A2 (en) * 2012-05-18 2013-11-21 The Cooper Health System A method of restoring endothelial/smooth muscle architecture and cell signaling pathways to sexual organs
EA202190962A2 (ru) 2014-05-30 2022-02-28 Оникс Терапьютикс, Инк. Уровни экспрессии иммуноглобулинов в качестве биологического маркера для реакции на ингибитор протеасом
CN105055450A (zh) 2015-02-13 2015-11-18 中国福利会国际和平妇幼保健院 人宫内膜干细胞在制备治疗卵巢早衰的药物中的应用

Also Published As

Publication number Publication date
US12496316B2 (en) 2025-12-16
CN111107858A (zh) 2020-05-05
SG11201912209UA (en) 2020-01-30
JP2020524179A (ja) 2020-08-13
TW201919664A (zh) 2019-06-01
WO2018236680A1 (en) 2018-12-27
ZA201908451B (en) 2021-05-26
EP3641793A1 (en) 2020-04-29
JP7343123B2 (ja) 2023-09-12
US20200129558A1 (en) 2020-04-30
CA3067354A1 (en) 2018-12-27
IL271395A (en) 2020-01-30
KR20200017516A (ko) 2020-02-18

Similar Documents

Publication Publication Date Title
US12496316B2 (en) Treatment of sexual dysfunction and improvement in sexual quality of life
US10660921B2 (en) Therapeutics using adipose cells and cell secretions
US20120201791A1 (en) Methods of treating diseases or conditions using mesenchymal stem cells
EP3299451B1 (en) Methods of using adipose tissue-derived cells in the treatment of raynaud's phenomenon
KR20140040696A (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR102895422B1 (ko) 세포성 및 체액성 면역을 도출하기 위한 인간 중간엽 줄기 세포의 사용 방법
JP2015159895A (ja) 脳梗塞治療のための多能性幹細胞
EP3474834B1 (en) Stimulating platelet formation with bezafibrate, resveratrol or srt1720 to treat thrombocytopenia
JP7591564B2 (ja) 変形性関節症を治療するための治療用アポトーシス細胞
JP2023002772A (ja) 脂肪細胞および細胞分泌物を使用する治療
KR101680834B1 (ko) 알파 리포산을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물
US20240065980A1 (en) Acellular compositions and methods
Protogerou et al. Stem cell therapy for erectile dysfunction: preliminary results from a single-center pilot study in Greece
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
EP4426816A1 (en) Primed uterine-derived regenerative cell compositions and uses thereof
WO2014047688A1 (en) Therapeutics using multiple injections of cells
KR20260004499A (ko) 인간 중간엽 줄기 세포를 사용하여 대상체에서 비-허혈성 확장형 심근병증을 치료하는 방법

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LONGEVERON LLC

Free format text: FORMER APPLICANT(S): DIFEDE, DARCY; LONGEVERON LLC

HB Alteration of name in register

Owner name: LONGEVERON INC.

Free format text: FORMER NAME(S): LONGEVERON LLC

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application